Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gefitinib vs gefitinib in EGFR-mutant NSCLC
CTR20201118Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of latanoprost, gefitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started Jun 2020; status: active.
02
Drugs
latanoprostgefitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20201118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201118.